Medtronic (NYSE:MDT) announced that the FDA approved its next-generation SynchroMed III intrathecal drug delivery system

The system offers a minimally invasive alternative to surgical resection and thermal ablation in patients with primary and metastatic liver cancers.

FluidAI’s first solution, Stream™ Platform, uses advanced sensors and an AI-driven algorithm that may prompt surgeons to identify these leaks earlier, helping surgeons achieve better clinical outcomes and efficiencies within the greater healthcare system.